Rare
lephants
Screener
Toggle theme
Niagen Bioscience, Inc.
NAGE
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
Total Cash from Operations:
$30.4M
Line Item
Value
% of Total
Other Investing
$292.0K
1.0%
Working Capital
$9.9M
32.8%
Net Cash Flow
$20.1M
66.3%
Download CSV
